id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-1995-0008,FDA,FDA-2020-E-1995,Letter from U. S. Patent and Trademark Office to Foley & Lardner LLP,Other,Letter(s),2024-02-21T05:00:00Z,2024,2,2024-02-21T05:00:00Z,,2024-02-21T21:47:05Z,,0,0,09000064863e85e4
FDA-2020-E-1995-0007,FDA,FDA-2020-E-1995,Notice of Final Determination Letter from U. S. Patent and Trademark Office to Foley & Lardner LLP,Other,Letter(s),2024-02-21T05:00:00Z,2024,2,2024-02-21T05:00:00Z,,2024-02-21T21:46:59Z,,0,0,09000064863e85e2
FDA-2020-E-1995-0006,FDA,FDA-2020-E-1995,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-07-13T04:00:00Z,2023,7,2023-07-13T04:00:00Z,,2023-07-13T16:41:29Z,,0,0,0900006485c9f74e
FDA-2020-E-1995-0005,FDA,FDA-2020-E-1995,Determination of Regulatory Review Period for Purposes of Patent Extension; NOURIANZ,Notice,Determinations,2022-11-07T05:00:00Z,2022,11,2022-11-07T05:00:00Z,2023-01-07T04:59:59Z,2022-11-07T18:21:13Z,2022-24217,0,0,0900006485492c81
FDA-2020-E-1995-0004,FDA,FDA-2020-E-1995,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-22T04:00:00Z,2022,9,2022-09-22T04:00:00Z,,2022-09-22T17:41:03Z,,0,0,0900006485350c90
FDA-2020-E-1995-0003,FDA,FDA-2020-E-1995,Letter from U S Patent and Trademark Office,Other,Letter(s),2021-02-23T05:00:00Z,2021,2,2021-02-23T05:00:00Z,,2021-02-23T17:02:48Z,,0,0,0900006484a49819
FDA-2020-E-1995-0002,FDA,FDA-2020-E-1995,Letter to U S Patent and Trademark Office,Other,Letter(s),2021-02-08T05:00:00Z,2021,2,2021-02-08T05:00:00Z,,2021-02-08T20:31:11Z,,0,0,0900006484a216e4
FDA-2020-E-1995-0001,FDA,FDA-2020-E-1995,Letter to U S Patent and Trademark Office,Other,Letter(s),2020-10-27T04:00:00Z,2020,10,2020-10-27T04:00:00Z,,2020-10-27T16:55:41Z,,0,0,09000064849378d2